This article is more than 5 years old. Information may no longer be current.
Anti-VEGF may treat subretinal neovascular membrane secondary to macular telangiectasia type 2
Visual acuity improved after intravitreal anti-VEGF monotherapy for the treatment of subretinal neovascular membrane secondary to macular telangiectasia type 2, according to a study.
“Our study supports the role of VEGF in the pathophysiology of [subretinal neovascular membrane], and we propose anti-VEGF drug monotherapy as the primary treatment for [subretinal neovascular membrane] secondary to [macular telangiectasia],” the study authors said.
The retrospective chart review included 16 eyes of 16 consecutive patients with treatment-naïve subretinal neovascular membrane secondary to macular telangiectasia. Four eyes were treated with intravitreal ranibizumab monotherapy and 12 were treated with intravitreal bevacizumab monotherapy. Mean follow-up was 12 months.
Mean BCVA improved significantly from 0.17 ± 0.16 at baseline to 0.27 ± 0.14 at final follow-up (P = .02). The mean number of intravitreal injections was 1.9.
The study was limited by its retrospective nature and small sample size, the authors noted.